Community-acquired pneumonia (CAP) presents diagnostic challenges in emergency departments, often leading to unnecessary antibiotic prescriptions and hospital admissions. A comprehensive care pathway and economic evaluation conducted using a UK NHS emergency departments perspective, demonstrates how MeMed BV host-response testing can transform CAP management by accurately differentiating bacterial from viral infections. This early-stage economic modeling study analyzed hypothetical cohorts of 1,000 adults and 1,000 children with suspected CAP, revealing substantial cost savings and improved patient outcomes when MeMed BV is integrated into standard care pathways.

Key Economic Model Projections:

• Substantial Cost Reduction: MeMed BV integration reduced total NHS costs by £134,018 for adults and £105,750 for children per 1,000 patients with suspected CAP
• Reduced Antibiotic Overuse: Testing led to decreased antibiotic treatments in 169 out of 1,000 adults and 121 out of 1,000 children, promoting antimicrobial stewardship
• Fewer Hospital Admissions: Hospital admissions decreased by 169 per 1,000 adults and 123 per 1,000 children, reducing healthcare burden
• Decreased Testing: Over 600 patients per 1,000 in both adult and pediatric cohorts required fewer additional diagnostic tests

Discover how MeMed BV can optimize your CAP management and reduce costs. Download the full economic analysis study